Abstract: A home analysis and display system and process includes receiving first data regarding home criteria. A pool of homes is assembled based on the first data, which includes a plurality of properties. The pool of homes is displayed, and a route for viewing the properties is determined. Feedback regarding the properties is received, and the pool of homes and/or the route is modified based on the received feedback.

Abstract: The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.

Abstract: The present invention relates to a group of compounds with a structural nucleus derived from phenylacetamide, having the following formula (I): that can modulate the DREAM neuronal calcium sensor. Consequently, the present invention also relates to the use of these compounds for the treatment or prevention of disorders or diseases in which DREAM levels are above or below physiologically normal levels.

Abstract: The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.

Abstract: The present invention relates to a group of compounds with a structural nucleus derived from phenylacetamide, having the following formula (I): that can modulate the DREAM neuronal calcium sensor. Consequently, the present invention also relates to the use of these compounds for the treatment or prevention of disorders or diseases in which DREAM levels are above or below physiologically normal levels.

Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that bivalently bind to homodimeric IL-17C.

Abstract: Inorganic nanoparticle, ferro-imogolite, for removing trace elements, comprising a nanohybrid containing magnetite/goethite and imogolite, a nanotubular aluminosilicate, in its structure, process for preparing an inorganic nanoparticle, and its use in removing trace elements.

Abstract: The invention relates to methods for determining the clinical outcome of a patient suffering ischemic stroke, for designing an individual therapy and for diagnosing a silent cerebrovascular disease comprising determining the levels of a marker selected from DPYSL2, gelsolin, CysA, or a combination thereof, the altered expression of which in relation to a reference value allows determining the clinical outcome of a patient suffering ischemic stroke, designing for designing an individual therapy or diagnosing a silent cerebrovascular disease. Furthermore, the invention relates to a kit comprising a reagent for detecting the level of a marker selected from DPYSL2, gelsolin, CysA, or a combination thereof and to the use of the said kit in the methods of the invention.

Abstract: Inorganic nanoparticle, ferro-imogolite, for removing trace elements, comprising a nanohybrid containing magnetite/goethite and imogolite, a nanotubular aluminosilicate, in its structure, process for preparing an inorganic nanoparticle, and its use in removing trace elements.

Abstract: The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.

Abstract: The present invention generally features therapeutic and diagnostic compositions and methods for increasing or decreasing the binding of a lysozyme polypeptide to a Treponema pallidum P17 polypeptide (Tp17) or a Tp17-like polypeptide. More particularly, the invention relates to compositions and methods for detecting, treating, or preventing a pathogen infection or a chronic disorder; and to binding assays using a Tp17-like polypeptide and a lysozyme polypeptide.

Abstract: The present invention relates to methods of diagnosis, therapy, and screening of new therapeutic compounds in the field of osteogenesis, based on the differential expression observed for the genes of the invention, represented by SEQ ID No 2, 7, 22, 25, 33, 35, 37, 38, 42, 47, 64, 69 or 77, 82, 97, 100, 108, 110, 112, 113, 117, 122, 139, 151, 158, 160, 172, 182, 184, 187, 188, 194.

Abstract: The present invention relates to methods of diagnosis, therapy, and screening of new therapeutic compounds in the field of osteogenesis, based on the differential expression observed for the genes of the invention, represented by SEQ ID No 1 to SEQ ID No 150, or SEQ ID No 151, 152 or 153, or SEQ ID No 154 to SEQ ID No 196, or SEQ ID No 197 to SEQ ID No 210, or SEQ ID No 211 to SEQ ID No 229, or SEQ ID No 230 to SEQ ID No 234, or SEQ ID No 235 to SEQ ID No 245.

Abstract: Medicaments for treating diabetic complications contain a compound of formula (A), wherein at least one Y or one Y′ is OH, and the remainder are selected from H, Hal, OH, OMe and NO2; X is O, S, keto or a direct link

Abstract: 1

Abstract: The present invention is directed to a novel depsipeptide has been isolated from a new marine strain L-13-ACM2-092 belonging to the family Micromonosporaceae. Its production by aerobic fermentation under controlled conditions of the strain, and the isolation and purification of PM-93135 are described herein. The compound and the fermentation broth demonstrate significant activity against several cancer cell lines. The compound also shows activity against several gram positive bacteria.

Abstract: The present invention is directed to a novel depsipeptide has been isolated from a new marine strain L-13-ACM2-092 belonging to the family Micromonosporaceae. Its production by aerobic fermentation under controlled conditions of the strain, and the isolation and purification of PM-93135 are described herein. The compound and the fermentation broth demonstrate significant activity against several cancer cell lines. The compound also shows activity against several gram positive bacteria.

Abstract: Burst alignment procedure between cordless terminals (T) and their base stations (BS), from which the cordless terminals (T) in question obtain the reference for their timebase. This burst alignment procedure is applicable in digital cordless communications systems with time division multiple access, to ensure the correct reception of the bursts received with different delays due to propagation effects. In this procedure, the cordless terminals (T) retransmit successively, up to a maximnum number of times, the first bursts to their base stations (BS), bringing them forward on each retransmission by a number of bits, depending on the inter-channel guard space, until an answer is received from their base stations (BS) once they are correctly synchronized with them.

Abstract: The present invention is directed to a novel depsipeptide has been isolated from a new marine strain L-13-ACM2-092 belonging to the family Micromonosporaceae. Its production by aerobic fermentation under controlled conditions of the strain, and the isolation and purification of PM-93135 are described herein. The compound and the fermentation broth demonstrate significant activity against several cancer cell lines. The compound also shows activity against several gram positive bacteria.